B-hCD19 MC38_Biocytogen Pharmaceuticals (Beijing) Co., Ltd._Biocytogen, drug development, antibody discovery

Please input keywords

Order

*Country

한국

미국

일본

중국

영국

호주

프랑스

독일

이탈리아

싱가포르

인도

러시아

캐나다

스위스

기타 국가

*Province

*City

*Name

*Telephone

*Company

*Position

*Email

*Verification code

*Verification Code

B-hCD19 MC38

Common name	B-hCD19 MC38	Catalog number	310706
Aliases	CD19, CD19 molecule, B4, CVID3	Disease	Colon carcinoma
Organism	Mouse	Strain	C57BL/6
Tissue types	Colon	Tissue	Colon

Description

The mouse Cd19 gene was replaced by human CD19 coding sequence in B-hCD19 MC38 cells. Human CD19 is highly expressed on the surface of B-hCD19 MC38 cells.

Application

B-hCD19 MC38 cells have the capability to establish tumors in vivo and can be used for efficacy studies.

Targeting strategy

Gene targeting strategy for B-hCD19 MC38 cells. The exogenous promoter and human CD19 coding sequence was inserted to replace part of murine exon 2 and all of exons 3~12. The insertion disrupts the endogenous murine Cd19 gene, resulting in a non-functional transcript.

Protein expression analysis

CD19 expression analysis in B-hCD19 MC38 cells by flow cytometry. Single cell suspensions from wild-type MC38 and B-hCD19 MC38 cultures were stained with species-specific anti-CD19 antibody. Human CD19 was detected on the surface of B-hCD19 MC38 cells but not wild-type MC38 cells. The 2-G1 clone of B-hCD19 MC38 cells was used for in vivo experiments.

Tumor growth curve & Body weight changes

from clipboard

Subcutaneous homograft tumor growth of B-hCD19 MC38 cells. B-hCD19 MC38 cells (5x10⁵) and wild-type MC38 cells (5x10⁵) were subcutaneously implanted into C57BL/6 mice (female, n=5). Tumor volume and body weight were measured twice a week. (A) Average tumor volume ± SEM. (B) Body weight (Mean± SEM). Volume was expressed in mm³ using the formula: V=0.5 X long diameter X short diameter². As shown in panel A, B-hCD19 MC38 cells were able to establish tumors in vivo and can be used for efficacy studies.

CD3e BsAb（Blinatumomab）efficacy

from clipboard

B-hCD19 MC38 cell line was subcutaneously implanted into B-hCD3E mice. Mice were grouped when tumor volume reached approximately 100 mm³, at which time they were treated with Blinatumomab with doses and schedules indicated in panel (B) Body weight changes during treatment. As shown in panel A, high dose of CD3e Bispecific Antibody(Blinatumomab) was efficacious in controlling tumor growth in B-hCD3E mice, demonstrating that the B-hCD19 MC38 were able to establish tumor in vivo and can be used for efficacy study.Values are expressed as mean ± SEM